ArticleJACC. Advances2025
Improving Cardiovascular Clinical Competencies for the Menopausal Transition: A Focus on Cardiometabolic Health in Midlife.
Article in JACC. Advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Preventive Cardiovascular Medication Prescribing Patterns in Menopausal Women.Mayo Clinic proceedings. Innovations, quality & outcomes · 2026Article
- Review
- Menopause Hormone Therapy After Spontaneous Coronary Artery Dissection: A Gap in the Literature.JACC. Advances · 2026Article
- Burden of subclinical coronary atherosclerosis among asymptomatic adults: the REACH-Rural India Study.The Lancet regional health. Southeast Asia · 2026Article
- Adiposity and domain-specific menopausal symptom severity in midlife women: a cross-sectional clinical study in eastern china.Frontiers in medicine · 2026Article
- Construction and verification of a prediction model for sleep disorders in older patients with coronary heart disease based on machine learning algorithms.Frontiers in medicine · 2026Article
- Advancing Preventive Cardiology: Innovations, Care Pathways, Global Challenges, and the Future of Cardiovascular Health Across the Life Course.JACC. Advances · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Cardiovascular disease (CVD) is the leading cause of death in women with an increase in risk after menopause. Over the past 20 years, longitudinal studies have helped differentiate the influence of chronological aging from ovarian aging on cardiovascular health. In addition to the pronounced sex hormone changes of the menopause transition (MT), the MT is also often accompanied by vasomotor symptoms, sleep problems, and mental health changes that impact women's cardiovascular health. The purpose of this invited review is to highlight the key changes that can alter CVD risk. Given the gaps in medical training, we also describe the need for specialized postgraduate curriculum in managing the MT with an aim to improve MT screening and management of CVD during this universal life stage. Finally, we propose a multidisciplinary approach led by experts in women's cardiovascular health and present an approach utilizing validated screening tools and CVD risk scores to discuss the candidacy of systemic menopause hormone therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.